Comparative Pharmacology
Head-to-head clinical analysis: ELOCON versus FLUONID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELOCON versus FLUONID.
ELOCON vs FLUONID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid